These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151 [TBL] [Abstract][Full Text] [Related]
3. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479 [TBL] [Abstract][Full Text] [Related]
4. PDGFRB disease: right diagnosis to prolong survival. Passamonti F Blood; 2014 Jun; 123(23):3526-8. PubMed ID: 24904095 [No Abstract] [Full Text] [Related]
5. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Metzgeroth G; Schwaab J; Gosenca D; Fabarius A; Haferlach C; Hochhaus A; Cross NC; Hofmann WK; Reiter A Leukemia; 2013 Nov; 27(11):2254-6. PubMed ID: 23615556 [No Abstract] [Full Text] [Related]
6. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402 [TBL] [Abstract][Full Text] [Related]
7. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533 [TBL] [Abstract][Full Text] [Related]
8. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Jawhar M; Naumann N; Schwaab J; Baurmann H; Casper J; Dang TA; Dietze L; Döhner K; Hänel A; Lathan B; Link H; Lotfi S; Maywald O; Mielke S; Müller L; Platzbecker U; Prümmer O; Thomssen H; Töpelt K; Panse J; Vieler T; Hofmann WK; Haferlach T; Haferlach C; Fabarius A; Hochhaus A; Cross NCP; Reiter A; Metzgeroth G Ann Hematol; 2017 Sep; 96(9):1463-1470. PubMed ID: 28725989 [TBL] [Abstract][Full Text] [Related]
9. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377 [TBL] [Abstract][Full Text] [Related]
10. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810 [TBL] [Abstract][Full Text] [Related]
11. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392 [TBL] [Abstract][Full Text] [Related]
12. Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement. Di Giacomo D; Quintini M; Pierini V; Pellanera F; La Starza R; Gorello P; Matteucci C; Crescenzi B; Fiumara PF; Veltroni M; Borlenghi E; Albano F; Forghieri F; Maccaferri M; Bettelli F; Luppi M; Cuneo A; Rossi G; Mecucci C Ann Hematol; 2022 Feb; 101(2):297-307. PubMed ID: 34859285 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453 [TBL] [Abstract][Full Text] [Related]
14. Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia. Xu X; Lu Q; Wang Z; Cai P; Zeng Z; Zhang L; Wang M; Ma L; Ruan C; Chen S Cancer Res Treat; 2021 Jul; 53(3):889-892. PubMed ID: 33421986 [TBL] [Abstract][Full Text] [Related]
15. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene. Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835 [TBL] [Abstract][Full Text] [Related]
16. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078 [TBL] [Abstract][Full Text] [Related]
17. [Pediatric myeloid neoplasms associated with eosinophilia and platelet-derived growth factor receptor beta gene rearrangement: a case report and literature review]. Zhang XY; Liu TF; Li CW; Li QH; Zhu XF Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):34-38. PubMed ID: 29342995 [No Abstract] [Full Text] [Related]
18. Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene. Yamazaki M; Nakaseko C; Takeuchi M; Ozawa S; Ishizuka Y; Hatanaka Y; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Ohwada C; Takeda Y; Mimura N; Iseki T; Fukazawa M; Sakaida E Intern Med; 2019 Dec; 58(23):3449-3453. PubMed ID: 31327842 [TBL] [Abstract][Full Text] [Related]
19. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Wilkinson K; Velloso ER; Lopes LF; Lee C; Aster JC; Shipp MA; Aguiar RC Blood; 2003 Dec; 102(12):4187-90. PubMed ID: 12907457 [TBL] [Abstract][Full Text] [Related]
20. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]